Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BEATRIZ ELENA ADRADA and GAIANE MARGISHVILI RAUCH.
BEATRIZ ELENA ADRADA
Connection Strength
6.628
GAIANE MARGISHVILI RAUCH
  1. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer. 2021 08 15; 127(16):2880-2887.
    View in: PubMed
    Score: 0.812
  2. Molecular Breast Imaging-guided Percutaneous Biopsy of Breast Lesions: A New Frontier on Breast Intervention. J Breast Imaging. 2020 Sep-Oct; 2(5):484-491.
    View in: PubMed
    Score: 0.774
  3. Comparison of Breast MR Imaging with Molecular Breast Imaging in Breast Cancer Screening, Diagnosis, Staging, and Treatment Response Evaluation. Magn Reson Imaging Clin N Am. 2018 May; 26(2):273-280.
    View in: PubMed
    Score: 0.661
  4. Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. Radiographics. 2023 10; 43(10):e230034.
    View in: PubMed
    Score: 0.241
  5. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiol Imaging Cancer. 2023 07; 5(4):e230009.
    View in: PubMed
    Score: 0.236
  6. Molecular Breast Imaging and Positron Emission Mammography. PET Clin. 2023 Oct; 18(4):487-501.
    View in: PubMed
    Score: 0.235
  7. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers (Basel). 2023 Feb 06; 15(4).
    View in: PubMed
    Score: 0.230
  8. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2022 12; 56(6):1901-1909.
    View in: PubMed
    Score: 0.218
  9. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022 Apr; 149:110220.
    View in: PubMed
    Score: 0.215
  10. MRI-guided Breast Biopsy Case-based Review: Essential Techniques and Approaches to Challenging Cases. Radiographics. 2022 Mar-Apr; 42(2):E46-E47.
    View in: PubMed
    Score: 0.215
  11. Imaging Surveillance of the Reconstructed Breast in a Subset of Patients May Aid in Early Detection of Breast Cancer Recurrence. J Clin Imaging Sci. 2021; 11:58.
    View in: PubMed
    Score: 0.211
  12. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
    View in: PubMed
    Score: 0.195
  13. High risk breast lesions identified on MRI-guided vacuum-assisted?needle?biopsy: outcome of surgical excision and imaging follow-up. Br J Radiol. 2018 Oct; 91(1090):20180300.
    View in: PubMed
    Score: 0.167
  14. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol. 2018 Jul; 25(7):1953-1960.
    View in: PubMed
    Score: 0.165
  15. MRI for the Staging and Evaluation of Response to Therapy in Breast Cancer. Top Magn Reson Imaging. 2017 Oct; 26(5):211-218.
    View in: PubMed
    Score: 0.159
  16. Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer. AJR Am J Roentgenol. 2017 Feb; 208(2):290-299.
    View in: PubMed
    Score: 0.149
  17. Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol. 2016 Feb; 23(2):482-9.
    View in: PubMed
    Score: 0.138
  18. Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Res Treat. 2014 Aug; 147(1):1-14.
    View in: PubMed
    Score: 0.127
  19. Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat. 2013 Jun; 139(3):639-47.
    View in: PubMed
    Score: 0.118
  20. Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol. 2023; 13:1264259.
    View in: PubMed
    Score: 0.060
  21. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.059
  22. Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annu Int Conf IEEE Eng Med Biol Soc. 2023 07; 2023:1-4.
    View in: PubMed
    Score: 0.059
  23. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.059
  24. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
    View in: PubMed
    Score: 0.058
  25. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
    View in: PubMed
    Score: 0.058
  26. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep. 2023 01 20; 13(1):1171.
    View in: PubMed
    Score: 0.057
  27. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer. 2023 Jan 10; 9(1):2.
    View in: PubMed
    Score: 0.057
  28. MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer Res. 2022 Sep 16; 82(18):3394-3404.
    View in: PubMed
    Score: 0.056
  29. Functional tumor diameter measurement with molecular breast imaging: development and clinical application. Biomed Phys Eng Express. 2022 08 12; 8(5).
    View in: PubMed
    Score: 0.056
  30. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell. 2022; 5:876100.
    View in: PubMed
    Score: 0.056
  31. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.055
  32. Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound Med Biol. 2022 06; 48(6):1010-1018.
    View in: PubMed
    Score: 0.054
  33. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.054
  34. The Challenging Image-Guided Preoperative Breast Localization: A Modality-Based Approach. AJR Am J Roentgenol. 2022 03; 218(3):423-434.
    View in: PubMed
    Score: 0.052
  35. Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer-weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study. Radiol Imaging Cancer. 2021 09; 3(5):e200155.
    View in: PubMed
    Score: 0.052
  36. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol. 2022 01; 29 Suppl 1:S35-S41.
    View in: PubMed
    Score: 0.052
  37. Imaging of Noncalcified Ductal Carcinoma In Situ. J Clin Imaging Sci. 2021; 11:34.
    View in: PubMed
    Score: 0.051
  38. Bracketing with Multiple Radioactive Seeds to Achieve Negative Margins in Breast Conservation Surgery: Multiple Seeds in Breast Surgery. Clin Breast Cancer. 2022 02; 22(2):e158-e166.
    View in: PubMed
    Score: 0.051
  39. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2021 07; 54(1):251-260.
    View in: PubMed
    Score: 0.050
  40. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020 Sep; 130:109170.
    View in: PubMed
    Score: 0.048
  41. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174.
    View in: PubMed
    Score: 0.044
  42. A pictorial?review: multimodality imaging of benign and suspicious?features of fat?necrosis in the breast. Br J Radiol. 2018 Dec; 91(1092):20180213.
    View in: PubMed
    Score: 0.042
  43. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
    View in: PubMed
    Score: 0.041
  44. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
    View in: PubMed
    Score: 0.039
  45. Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up. AJR Am J Roentgenol. 2017 Apr; 208(4):916-922.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.